May 15, 2007 by Mike HavrillaEyeing ISISA robust pipeline and a promising cholesterol drug could benefit the pharmaceutical firm.
May 15, 2007 by Mike HavrillaA Tale of Two Trials at YM BioEncouraging results and ongoing drug trials give YM BioSciences investors hope .
May 15, 2007 by Mike HavrillaRisky Bet OraSure Thing?The company strides forward to offer quick, less invasive methods of testing for disease and drugs.
May 15, 2007 by Mike HavrillaA Heads-Up on TorreyPinesIts tezampanel for migraines shows promise after some trials.
May 15, 2007 by Mike HavrillaOn the Threshold at SonusIt's testing one drug that could be used to treat several types of cancer.
May 14, 2007 by Mike HavrillaA Weaker AmgenThe stock is trading lower after an FDA panel balked at two anemia drugs.
May 14, 2007 by Mike HavrillaInvestors Tire of Inspire PharmaceuticalsShares are down about 10% recently, despite approval for AzaSite.
May 9, 2007 by Mike HavrillaA Hard Sell at North PittHedge fund activist shareholders push for a sale of the company.
May 9, 2007 by Mike HavrillaScintillating SyntaPatient investors should peek at this promising pipeline.
May 8, 2007 by Mike HavrillaIs VISICU on the Verge?There are some positive developments regarding a key patent.
May 7, 2007 by Mike HavrillaAdvanced Life Makes ProgressAfter positive data in an anthrax study, the company's potential antibiotic cethromycin has been granted FDA Orphan Drug status for this indication.
May 7, 2007 by Mike HavrillaOscillating OscientShares of the tiny drug company have been highly volatile for several reasons.
May 7, 2007 by Mike HavrillaCritical Therapeutics' JunctureWith approval likely, the real challenge will be selling an asthma drug once it's on the market.
May 4, 2007 by Mike HavrillaTaking It to the AffymaxPositive clinical data for a potential anemia treatment has the drugmaker's stock on the rise.
May 4, 2007 by Mike HavrillaOn Deck in BiotechInvestors can keep an eye on possible catalysts for these stocks in the next week.
May 3, 2007 by Mike HavrillaAltus Could Rise to New HeightsAltus stands to gain ground if it can successfully advance its two leading drug candidates through clinical trials later this year.
May 2, 2007 by Mike HavrillaAn Eye-Opening Potential AcquisitionBiotech firm Inspire should consider buying drug-development partner InSite Vision.
May 2, 2007 by Mike HavrillaHeads Up, Biotech Investors: Chapter 2Get to know the timing of major catalysts for stocks that may be on your biotech watch list.
